Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280148 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Hongyi Dammu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America. Hauptthemen laut MEDLINE: Breast Neoplasms, Deep Learning. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
The goal of this study was to employ novel deep-learning convolutional-neural-network (CNN) to predict pathological complete response (PCR), residual cancer burden (RCB), and progression-free survival (PFS) in breast cancer patients treated with neoadjuvant chemotherapy using longitudinal multiparametric MRI, demographics, and molecular subtypes as inputs. In the I-SPY-1 TRIAL, 155 patients with stage 2 or 3 breast cancer with breast tumors underwent neoadjuvant chemotherapy met the inclusion/exclusion criteria. The inputs were dynamic-contrast-enhanced (DCE) MRI, and T2- weighted MRI as three-dimensional whole-images without the tumor segmentation, as well as molecular subtypes and demographics. The outcomes were PCR, RCB, and PFS. Three (“Integrated”, “Stack” and “Concatenation”) CNN were evaluated using receiver-operating characteristics and mean absolute errors. The Integrated approach outperformed the “Stack” or “Concatenation” CNN. Inclusion of both MRI and non-MRI data outperformed either alone. The combined pre- and post-neoadjuvant chemotherapy data outperformed either alone. Using the best model and data combination, PCR prediction yielded an accuracy of 0.81±0.03 and AUC of 0.83±0.03; RCB prediction yielded an accuracy of 0.80±0.02 and Cohen’s κ of 0.73±0.03; PFS prediction yielded a mean absolute error of 24.6±0.7 months (survival ranged from 6.6 to 127.5 months). Deep learning using longitudinal multiparametric MRI, demographics, and molecular subtypes accurately predicts PCR, RCB, and PFS in breast cancer patients. This approach may prove useful for treatment selection, planning, execution, and mid-treatment adjustment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America.
ORCID-Profile: Tim Q Duong
Zitieren
APA
Dammu, H., Ren, T., & Duong, T. Q. (2023). Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0280148
Vancouver
Dammu H, Ren T, Duong TQ. Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients. PLOS ONE. 2023. doi:10.1371/journal.pone.0280148
BibTeX
@article{Dammu2023,
author = {Dammu, Hongyi and Ren, Thomas and Duong, Tim Q},
title = {Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280148}
}
EUVIMED